logo
Plus   Neg
Share
Email

Genentech: Phase III PEMPHIX Study With Rituxan Meets Primary End Point

Genentech, affiliated to Swiss drug major Roche Group (RHHBY), announced Thursday that the Phase III PEMPHIX Study with Rituxan (Rituximab) in patients with Pemphigus Vulgaris or PV met the primary and secondary endpoints.

The study evaluated the efficacy and safety of Rituxan compared to mycophenolate mofetil or MMF that is accepted as standard of care.

Rituxan demonstrated that it is superior to standard of care in achieving sustained remission in adults with moderate to severe PV.

Genentech will present the complete data from the PEMPHIX study at an upcoming medical congress. The results will be submited to health authorities around the world, including the U.S. Food and Drug Administration.

In June 2018, Rituxan became the first and only biologic therapy approved by the FDA for the treatment of PV based on results from the Ritux 3 clinical trial. The latest PEMPHIX trial provided additional clinical evidence on the effectiveness of Rituxan for PV.

PV is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Goldman Sachs Group Inc. (GS) reported Tuesday a profit for the second quarter of 2019 that declined 6 percent from last year. However, profit topped analysts' estimates. Quarterly net revenues also decreased 2 percent. The company raised its quarterly dividend by 47 percent. While reporting financial results for the second quarter, Johnson & Johnson (JNJ) on Tuesday maintained its adjusted earnings forecast for the full year 2019, while raising sales outlook. For fiscal 2019, the company maintained its outlook for adjusted earnings in the range of $8.53 to $8.63 per share.... Canada's new regulations that provide extra protection for airline passengers will kick in Monday, July 15. The new rules from the Canada Transportation Agency, which has received severe backlash from industry and consumer advocates, requires airlines to compensate passengers up to $2,400 if they...
Follow RTT